Brugada syndrome (BrS) is classically inherited as an autosomal dominant trait, with age- and sex-related penetrance, and is associated with an increased incidence of sudden cardiac death (SCD), which is often nocturnal, and is usually in persons with a structurally normal heart. The diagnosis of BrS is made when a type 1 pattern with coved ≥2 mm ST elevation in ≥1 right precordial leads is seen at rest or on provocation with a sodium channel blocker (procainamide USA; Ajmaline Europe) on surface 12-lead ECG (in the usual position of the fourth intercostal space (ICS) or by moving leads V1 and V2 to the second and third ICS) (Priori et al. 2013).